

ELITE PHARMACEUTICALS INC /DE/
Form SC 13G
July 13, 2010

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 13G
(RULE 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED
PURSUANT TO RULE 13d-1(b), (c) AND (d)
AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b)

ELITE PHARMACEUTICALS, INC.
(Name of Issuer)

COMMON STOCK, \$0.001 PAR VALUE
(Title of Class of Securities)

28659T200
(CUSIP Number)

July 9, 2010
(Date of event which requires filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
- Rule 13d-1(c)
- Rule 13d-1(d)

(Continued on following pages)
(Page 1 of 5 Pages)

1. NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Midsummer Investment Ltd.
 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a)
(b)
 3. SEC USE ONLY
 4. CITIZENSHIP OR PLACE OF ORGANIZATION:
Bermuda
- | | | |
|-------------------------------------------------------------------------------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5. 6. 7. 8. | SOLE VOTING POWER 8,661,136 SHARED VOTING POWER None. SOLE DISPOSITIVE POWER 8,661,136 SHARED DISPOSITIVE POWER None. |
|-------------------------------------------------------------------------------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
8,661,136
 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
9.3% (1)
 12. TYPE OF REPORTING PERSON: OO

(1) The ownership percentage of the Reporting Person is based on 92,656,745 shares of Common Stock issued and outstanding as of July 9, 2010 as stated in writing by the Issuer's Chief Financial Officer on July 12, 2010.

Item 1(a). Name of Issuer.

Elite Pharmaceuticals, Inc. (the "Issuer")

Item 1(b). Address of Issuer's Principal Executive Offices.

165 Ludlow Avenue, Northvale, New Jersey 07647

Item 2(a). Names of Person Filing.

Midsummer Investment Ltd. ("Midsummer Investment")

Item 2(b). Address of Principal Business Office, or if none, Residence.

Midsummer Investment Ltd.
c/o Midsummer Capital, LLC
295 Madison Ave, 38th Floor
New York, NY 10017

Item 2(c). Citizenship or Place of Organization.

Bermuda

Item 2(d). Title of Class of Securities.

Common Stock, \$0.001 par value (the "Common Stock")

Item 2(e). CUSIP Number.

28659T200

Item 3. If this statement is filed pursuant to Rules 13d-1(b) or 13d-2(b), check whether the person filing is a:

Not applicable.

Item 4. Ownership.

As of the date hereof, Midsummer Investment beneficially owns 8,661,136 shares of Common Stock of the Issuer.

Midsummer Capital, LLC ("Midsummer Capital") is the investment advisor to Midsummer Investment. By virtue of such relationship, Midsummer Capital may be deemed to have dispositive power over the shares owned by Midsummer Investment. Midsummer Capital disclaims beneficial ownership of such shares. Mr. Michel Amsalem and Mr. Joshua Thomas have delegated authority from the members of Midsummer Capital with respect to the shares of Common Stock owned by Midsummer Investment. Messrs. Amsalem and Thomas may be deemed to share dispositive power over the shares of common stock held by Midsummer Investment. Messrs. Amsalem and Thomas disclaim beneficial ownership of such shares of Common Stock, and neither person has any legal right to maintain such delegated authority.

Accordingly, for the purpose of this Statement:

- (a) Amount beneficially owned by Midsummer Investment: 8,661,136 shares of Common Stock of the Issuer.
- (b) Percent of Class: Midsummer Investment beneficially owns 9.3% of the Issuer's issued and outstanding Common Stock (based on 92,656,745 shares of Common Stock issued and outstanding as of July 9, 2010 as stated in writing by the Issuer's Chief Financial Officer on July 12, 2010).
- (c) Number of shares as to which Midsummer Investment has:
 - (i) Sole power to direct the vote: 8,661,136 shares of Common Stock of the Issuer.
 - (ii) Shared power to vote or to direct the vote: None.
 - (iii) Sole power to dispose or direct the disposition of the Common Stock: 8,661,136 shares of Common Stock of the Issuer.
 - (iv) Shared power to dispose or direct the disposition of the Common Stock: None.

Item 5. Ownership of Five Percent or Less of a Class.

Not applicable.

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

Not applicable.

Item 8. Identification and Classification of Members of the Group.

Not applicable.

Item 9. Notice of Dissolution of Group.

Not applicable.

Item 10. Certification.

By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction which could have that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: July 12, 2010

MIDSUMMER INVESTMENT LTD.

By: /s/ Michel A. Amsalem
Name: Michel A. Amsalem
Title: President
